SOLIGENIX, INC. Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31)
SOLIGENIX, INC. (SNGX) reported Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) of 1.38% for the 12-month period ending 2014-12-31, per its 10-Q filed 2015-05-14.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueAssumptionsRiskFreeInterestRate · last filed 2015-05-14
- SOLIGENIX, INC. fair value assumptions, risk free interest rate (deprecated 2018-01-31) for fiscal 2013 was 1.75%.
| Period end | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 1 month | Fair Value Assumptions, Risk Free Interest Rate (Deprecated 2018-01-31) 12 month |
|---|---|---|
| 2014-12-31 | 1.38% 10-Q · filed 2015-05-14 | |
| 2013-12-31 | 1.75% 10-K · filed 2015-03-25 | |
| 2013-06-25 | 1.49% 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |